Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension

Am J Respir Crit Care Med. 2014 Jun 1;189(11):1435-6. doi: 10.1164/rccm.201311-2019IM.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antihypertensive Agents / therapeutic use
  • Arteriovenous Malformations / diagnosis
  • Arteriovenous Malformations / genetics*
  • Arteriovenous Malformations / therapy
  • Bone Morphogenetic Protein Receptors, Type II / genetics*
  • Bosentan
  • Disease Progression
  • Drug Therapy, Combination
  • Familial Primary Pulmonary Hypertension
  • Follow-Up Studies
  • Humans
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / genetics*
  • Hypertension, Pulmonary / therapy
  • Male
  • Middle Aged
  • Mutation*
  • Pedigree
  • Piperazines / therapeutic use
  • Pulmonary Artery / abnormalities*
  • Pulmonary Veins / abnormalities*
  • Purines / therapeutic use
  • Sildenafil Citrate
  • Sulfonamides / therapeutic use
  • Sulfones / therapeutic use
  • Treatment Outcome
  • Vasodilator Agents / therapeutic use

Substances

  • Antihypertensive Agents
  • Piperazines
  • Purines
  • Sulfonamides
  • Sulfones
  • Vasodilator Agents
  • Sildenafil Citrate
  • BMPR2 protein, human
  • Bone Morphogenetic Protein Receptors, Type II
  • Bosentan